TendieTensor TendieTensor
You’re browsing as
Guest
Free Preview
Sign in/sign up to unlock all features.

News  ›  GlobeNewswire Inc.

ALVO Investor News: If You Have Suffered Losses in Alvotech (NASDAQ: ALVO), You Are Encouraged to Contact The Rosen Law Firm About Your Rights

GlobeNewswire Inc. Logo GlobeNewswire Inc. By Rosen Law Firm
ALVO Investor News: If You Have Suffered Losses in Alvotech (NASDAQ: ALVO), You Are Encouraged to Contact The Rosen Law Firm About Your Rights

The Rosen Law Firm is investigating potential securities claims against Alvotech (NASDAQ: ALVO) following the company's November 2, 2025 announcement that the FDA issued a complete response letter for its AVT05 biologics license application, citing manufacturing deficiencies. The stock fell 34% on November 3, 2025, and investors are being encouraged to join a prospective class action lawsuit.

Insights
ALVO   negative

The company received an FDA complete response letter indicating manufacturing deficiencies that must be resolved before BLA approval, resulting in a 34% stock price decline. This regulatory setback and subsequent securities investigation indicate significant negative developments for the company and its investors.